Leader in
Scientific Marketing

Carsten Thiel

Carsten Thiel’s career within the realm of biomedicine, pharmaceutical marketing, and the medical sector spans many years, and touches upon various disciplines related to the field. This myriad of experiences, combined, has allowed Thiel to flourish within his field, and to become a leader in scientific marketing.

Born in Berlin, Thiel’s family lineage was rich with medical professionals, including his medic mother and father. Enthralled with DNA, and the concept of a pre-written manifest destiny for each individual, Thiel excelled throughout his education, setting the undoubtable path to remain within a not-yet-decided aspect of the medical field. Thiel initially pursued studies in Chemistry in his native country’s Malbrook, before exploring an Anglo-Saxon educational experience within the United Kingdom’s University of Bristol. Focused on the study of biochemistry, Thiel earned his Bachelor of Science degree, and forged ahead into post-undergraduate education.

Carsten Thiel attended the prestigious Max Planck Institute For Biophysical Chemistry, an elite research organization in Germany. Specializing in molecular biology, Thiel studied proteins involved in the morphing of healthy cells into cancerous cells. Thiel earned his PhD, and entered the workforce post-matriculation via the highly innovative pharmaceutical giant Hoffman la-Roche.

Early within his career as a Communications and Product Manager, Thiel parlayed his knowledge of scientific marketing, consumer culture, medical insight, and patient-first code of ethics into a swiftly rising career. Less than a year later, Thiel was provided with the vastly important duty of spearheading the initial product launch of the company’s first foray into the weight-loss sector, via new product Xenical. Thiel’s expertise, leadership style, and knowledge created a stellar initial launch for the product, with first year sales surpassing one billion Swiss francs. Most importantly, however, the product was well received within the mass market, and retained a positive consumer reputation.

After his initial foray into launching new products, Thiel excelled within this role throughout several years, launching many breakthrough innovations throughout various niche fields of the medical sector. Believing in the credo that these new treatments would assist thousands of patients, Thiel continuously sought ways to provide meaningful aid to all individuals through training prescribers, and ensuring unparallelled quality control standards.


EUSA Pharma Names Industry Veterans to Newly Created Posts

EUSA Pharma names industry veterans to newly-created posts

UK and USA-based specialty drugmaker EUSA Pharma today announced the strengthening of its senior leadership… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.

Curating a Career: Carsten Thiel’s Purposeful Exploration of Pharma

Curating a Career: Carsten Thiel’s Purposeful Exploration of Pharma – Doug Sandler Blog

Through an average career cycle, one can ebb and flow with the change of tides, finding themselves accidentally in various positions. With just enough sheer luck, one may even find advancement in a given field, acquiring just enough knowledge, insight, and experience required to perform all required

EUSA Gains New President, Carsten Thiel Gains New Perspective

New York City, NY Patch – Breaking News, Local News, Events, Schools, Weather, Sports and Shopping

Local news and events from New York City, NY Patch. Latest headlines: NYC’s Most Popular Area For Homebuyers Isn’t The One You’d Expect; Presidents’ Day In NYC: What’s Open And Closed

Carsten Thiel: People on The Move – New York Business Journal

Carsten Thiel | People on The Move – New York Business Journal

Newly appointed President Europe of rapidly expanding global specialized pharmaceutical giant EUSA, which focuses on treatment and cure of rare diseases and oncology care, Carsten Thiel brings over twenty years of pertinent experience within the pharmaceutical sector to his new role.